Gynecologic CancerSERENITYNCT04564768
The SERENITY Study: Online Mindfulness-Based Cancer Recovery for Patients With Gynecological Cancer
A study testing Online Mindfulness-Based Cancer Recovery (MBCR) in people with Gynecologic Cancer, run by University Hospital, Geneva at 2 sites in Switzerland.
Trial summary
The overall objective of this project is to explore the feasibility, acceptability and potential effects of the online MBCR program in gynecological cancer settings. This will provide preliminary efficacy data in prevision of a larger, confirmatory, randomized controlled trial. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Gynecologic Cancer
- What is being tested?
- Online Mindfulness-Based Cancer Recovery (MBCR)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 62 participants
- Where
- 2 sitesSwitzerland
- Study dates
- 19 Dec 2019to 30 Sep 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥ 18 years
- Being a woman
- Being diagnosed with breast or any gynecological cancer (either ovarian, cervical, vulvar, womb or vaginal cancer), stages I to IV.
- For women with localized cancers: having completed all adjuvant treatments, such as surgery, chemotherapy and/or radiotherapy, at least 3 months previously, with the exception of hormonal, immune and targeted therapy,
- For women with metastatic cancers: having a performance status < 3, not undergoing IV chemotherapy and having a life expectancy more than 9 months as estimated by their treating oncologist.
- Free from acute infection for 2 weeks before biochemical assessment.
- Speaking and reading French fluently
- Be able to follow the online course via a computer/tablet
Who cannot join
- Inability to follow the procedures of the study due to:
- Significant deafness
- Physical impairment that prevents attending the sessions
- Mental retardation (ICD-10)
- Dementia (ICD-10)
- Depression (ICD-10) *
Show all 13Show fewer
- Spectrum disorder of schizophrenia (ICD-10) **
- Alcohol or other substance dependence (ICD-10) **
- Emotionally labile personality disorder that is incompatible with group participation (ICD-10) **
- A post-traumatic stress disorder (PTSD) (ICD-10)**
- Currently engages in meditation one or more times per week
- Previous participation in an MBI program
- Serious physiological illnesses that would interfere with the interpretation of biochemical data (e.g., anemia, diabetes, cardiovascular diseases, blood cancers, inflammatory bowel diseases, autoimmune diseases, asthma being treated with steroids, immunodeficiency)
Trial locations and contacts
2 sites in 1 country.
Switzerland2 sites
Hôpitaux Universitaires de Genève (HUG)
Geneva
Centre Hospitalier Universitaire Vaudois (CHUV)
Lausanne
About this study
Official title: Online Mindfulness-Based Cancer Recovery (MBCR) Program for Patients Living With a Gynecological Cancer: a Pilot Randomized Controlled Study.
The overall objective of this project is to explore the feasibility, acceptability and potential effects of the online MBCR program in gynecological cancer settings. This will provide preliminary efficacy data in prevision of a larger, confirmatory, randomized controlled trial. As this study will be one of the first led in a French speaking country and the first conducted in a university hospital environment in Switzerland, the investigators would like to investigate the early implementation of this program among professionals and patients. Furthermore, they will investigate if in the online MBCR group, participants will show improvement in psychosocial outcomes, consumption of psychotropic and opioid medication, spirituality and meaning in life and in different biological processes.
- Conditions
- Gynecologic Cancer
- Being tested
- Online Mindfulness-Based Cancer Recovery (MBCR)
- Keywords
- Online Mindfulness-Based Cancer Recovery
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Online Mindfulness-Based Cancer Recovery (MBCR)Behavioural
Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
| Study group | Role | What they receive |
|---|---|---|
| Intervention group | Experimental | Online Mindfulness-Based Cancer Recovery Receives: Behavioral: Online Mindfulness-Based Cancer Recovery (MBCR) |
| Control group | No intervention | Treatment as usual |
What is being measured
The primary outcome is the main question the study is designed to answer.
Participants' attendance to the program
Number of overall sessions attended - patients are expected to attend at least 5 of the 10 sessions planned (including the 6-h retreat)
Measured: Within 3 weeks of completion of the intervention
Secondary outcomes (27)
Acceptability of the program (quantitative)
Frequency, duration and type of mindfulness exercises practiced each day during the MBCR program will be gathered every week with an unobtrusive data collection method: the log. One week after the end of the program (t1), participants will be invited to fill an evaluation form of the program: a self-administered survey of 5-points Likert scale (19 items). Questions are related to the content and the structure of the program.
Measured: Every week during the intervention and within 3 weeks of completion of the intervention
Acceptability of the program (qualitative)
Qualitative data will also be collected at t1 through a thematic semi-structured interview of approximately 30-45 minutes with participants. Moreover, focus groups with the clinical staff will be performed at t1 to understand their overall perception of the facilitators and barriers related to the program (that might explain the acceptability of the intervention at the organizational level).
Measured: Every week during the intervention and within 3 weeks of completion of the intervention
Appropriateness of the program (quantitative)
Perceived fit, usefulness and practicability of the program will be explored with the participants through the survey.
Measured: Within 3 weeks of completion of the intervention
Appropriateness of the program (qualitative)
At t1, semi-structured interviews will be performed with the program instructors to explore their perception of the appropriateness of the program with the specific population.
Aforementioned focus groups with the clinical staff performed at t1 will help to understand this outcome as well.
Measured: Within 3 weeks of completion of the intervention
Fidelity of the program
Instructors' adherence to the program protocol: two-three experts will judge instructors' fidelity to the program, by assessing recorded sessions, based on the Mindfulness-Based Interventions Teaching Assessment Criteria (MBI-TAC).
Measured: Within 3 weeks of completion of the intervention
Adoption of the program (from participants' perspectives)
At t2 (3 months post-intervention): participants will be asked about their mean meditation practice during the last two weeks.
Measured: Organizational: within 3 weeks of completion of the intervention ; participants: 3-month follow up from intervention completion
Adoption of the program (from professionals' perspectives)
At t1, clinical staff's intention to adopt the online program in their institution will be explored through the focus group aforementioned.
Measured: Organizational: within 3 weeks of completion of the intervention ; participants: 3-month follow up from intervention completion
Costs of the program
Costs will be tracked regarding the price of the material, instructors' training, other resources (e.g. insurance reimbursement possibilities).
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Time to recruit, recruitment, retention rates, reasons for non-participation and acceptability of data collection
Time to recruit, recruitment and retention rates will be gathered through administrative data during (pre)screening, enrollment, allocation and follow-up. Reasons for non-participation, intervention/study dropouts will be collected when possible. Acceptability of data collection will be retrieved through missing data within questionnaires.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Acceptability of the study processes
Acceptability of the study processes will be explored through qualitative data collection aforementioned with the participants, instructors and stakeholders. Moreover, the control group will be invited to a semi-structured interview at t2 to explore their perception of the study processes (e.g. acceptability to be on a wait-list).
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Patients' experience related to the online MBCR program and the study design
Overall experience will be explored with participants during the interviews aforementioned.
Measured: Within 3 weeks of completion of the intervention
State and Trait Anxiety Inventory Form Y (STAI-Y)
The STAI-Y is a self-report questionnaire measuring the severity of current anxiety symptoms (The State Anxiety Scale - S-Anxiety, composed of 20 items with 10 reversed items) and the generalized tendency to be anxious (The Trait Anxiety Scale - T-Anxiety, composed of 20 items with 9 reversed items) (40 items in total). A high score indicating the presence of anxiety. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Major Depression Inventory (MDI)
The MDI is a self-report mood questionnaire developed with the WHO. It is composed of 12 items. The MDI used as a diagnostic scale for depression (by following the algorithms in accordance with DSM-IV or ICD-10) and also as a measure of depression severity via its summed total score (ranging from 0 to 50). Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Five Facet Mindfulness Questionnaire (FFMQ)
The FFMQ is a self-administered questionnaire that measures five components: (a) the ability to observe, note, pay attention to sensations, perceptions, thoughts and feelings feelings/emotions, b) the ability to describe, c) the ability to act consciously, autopilot, concentration, non-distraction, d) ability to describe, put into words, and e) non-responsiveness to experiences internal. The FFMQ-SF is composed of 39 items. Items are rated on a 5-point Likert scale ranging from 1 (never or rarely true) to 5 (very often or always true). A higher score indicating a greater engagement with mindfulness skills. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Sleep Condition Indicator (SCI)
The SCI is an 8 items self-administered questionnaire that evaluate difficulty in initiating sleep, maintaining sleep, sleep quality, daytime sleep-related symptoms, duration of sleep problems, nights per week having a sleep disturbance, and extent troubled by poor sleep on a five-point Likert scale (0.4). Total scores range from 0 to 32, with lower scores indicating worse sleep. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Posttraumatic Growth Inventory - Revised (PTGI-R)
The PTGI-R is a questionnaire to assess the benefits of a traumatic experience such as cancer on, for example, relationships with others, inner strength, changes in spirituality, appreciation of life or new perspectives. The PTGI-R consists of 21 items, and each item is rated on a 6-point scale ranging from 0 (no change) to 5 (great change). A higher score indicating a greater posttraumatic growth. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Self-Compassion Scale (SCS)
The SCS is a self-administered 26-items questionnaire measuring 6 dimensions: a) self-worth, b) self-judgement, c) the common humanity, d) isolation, e) mindfulness, and f) over-identification. A total score of self-compassion can be calculated and ranges from 1 (almost no self-compassion) to 5 (constant self-compassion). A higher score indicating a higher level of self-compassion. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Fear of Cancer Recurrence Inventory (FCRI)
The FCRI is a self-report questionnaire with 42 items across 7 dimensions of FCR that evaluate: the presence of potential stimuli activating FCR; the presence and severity of intrusive thoughts or images associated with FCR; psychological distress associated with FCR; coping strategies that can be used to cope with FCR; the level of insight towards FCR; reassurance behaviors associated with FCR; and the level of functioning impairment associated with FCR. For this study, we will only focus on the 3 items of Factor 6 (level of insight towards FCR). The higher the score, the greater the participants' fear of recurrence. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
The EORTC QLQ-C30 is a self-administered quality of life assessment questionnaire for cancer patients. It reflects the impact of care strategies on quality of life in its multidimensional aspect. It is composed of 5 functional scales ((1) functional ability, (2) ability to accomplish any form of work and leisure activity, (3) emotional state, (4) cognitive ability, (5) ability to maintain relationships), 3 symptom scales ((1) fatigue, (2) nausea and vomiting, (3) pain), different items measuring the symptoms usually encountered in cancer patients and an overall health and quality of life scale overarching. All of the scales and single-item measures range in score from 0 to 100. A higher score indicating better quality of life. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being (FACIT-Sp12)
The FACIT-Sp12 is a twelve item self-administered questionnaire with a 5 point Likert scale.The instrument was designed to provide an inclusive measure of spirituality that could be employed in research with people with chronic and/or life-threatening illnesses. It comprises two subscales, one reflects a sense of meaning and peace and the other assessing the role of faith in illness. It is predictive of quality of life in breast cancer survivors, adjustment to cancer and decline of depressive symptoms and reduced long-term care. 7 of the 12 items specifically investigate a current spiritual state. A higher score indicating a better spiritual well-being. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Immune cells count
Will be determined by flow-cytometry. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Circulating pro-inflammatory markers (1)
Plasma levels of several cytokines (such as IL-6 and TNF-α) will be determined by high sensitivity ELISA. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Circulating pro-inflammatory markers (2)
CRP will be determined by high sensitivity ELISA. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Gene expression of pro-inflammatory genes
RNA will be extracted from PBMC using Qiagen RNEasy kit. RNA will be subject to genome-wide transcriptional profiling (RNA sequencing). Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Telomerase activity
Will be quantified from PBMC pellets using the Telomeric Repeat Amplification Protocol (TRAP)eze®RT: Telomerase Detection Kit. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Telomere length
Will be measured with a quantitative real-time PCR assay that determines the relative ratio of telomere repeat copy number to single-copy gene (human β globin) number (T/S ratio) in experimental samples as compared to a reference DNA sample. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Methylation of inflammatory genes
Methylation assays will cover key regions found to be differentially methylated in previous studies such as IL-6, TNF and CRP and other genes of interest to be determined. DNA will be extracted using the QIAamp DNA Mini Kit and bisulphite converted using the MethylEasy Xceed Kit. Linear mixed modelling will be used to assess change over time.
Measured: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2020
- Study start19 Dec 2019
- Primary completion30 Jun 2022
- Study completion30 Sep 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gynecologic CancerStudies of the same condition, open and under way.
- More trials run by University Hospital, GenevaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A randomized controlled pilot study including qualitative and quantitative elements.
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 62 participants (actual)
Sponsor and investigators
- Lead sponsor
- University Hospital, Geneva
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Marie-Estelle Gaignard, University Hospital, Geneva
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04564768
- Sponsor's protocol ID
- 2019-00965
- Other IDs
- 2019
- Acronym
- SERENITY
- Status last verified
- Nov 2022
- First submitted
- 22 Aug 2020
- Last updated
- 29 Nov 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Gaignard ME, Martin D, Stanic J, Hilfiker R, Bodmer A, Ljuslin M, Zaman K, Labidi-Galy I, Sarivalasis A, Carlson LE, Peters S, Dietrich PY, Eicher M, Bondolfi G, Jermann F. The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial. Psychooncology. 2025 Nov;34(11):e70334. doi: 10.1002/pon.70334.
PubMed 41272951
Study at a glance
From the registry record, last updated by the sponsor on 29 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Online Mindfulness-Based Cancer Recovery (MBCR) Program for Patients Living With a Gynecological Cancer: a Pilot Randomized Controlled Study.
- ClinicalTrials.gov ID
- NCT04564768
- Acronym / sponsor ID
- SERENITY / 2019-00965
- Conditions
- Gynecologic Cancer
- Keywords
- Online Mindfulness-Based Cancer Recovery
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 62 participants (actual)
- Lead sponsor
- University Hospital, GenevaUniversity, hospital or other
- Study start
- 19 Dec 2019 (actual)
- Primary completion
- 30 Jun 2022 (actual)
- Study completion
- 30 Sep 2022 (actual)
- First posted
- 25 Sep 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall objective of this project is to explore the feasibility, acceptability and potential effects of the online MBCR program in gynecological cancer settings. This will provide preliminary efficacy data in prevision of a larger, confirmatory, randomized controlled trial. As this study will be one of the first led in a French speaking country and the first conducted in a university hospital environment in Switzerland, the investigators would like to investigate the early implementation of this program among professionals and patients. Furthermore, they will investigate if in the online MBCR group, participants will show improvement in psychosocial outcomes, consumption of psychotropic and opioid medication, spirituality and meaning in life and in different biological processes.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- A randomized controlled pilot study including qualitative and quantitative elements.
| Arm | Type | Receives |
|---|---|---|
| Intervention group | Experimental | Behavioral: Online Mindfulness-Based Cancer Recovery (MBCR)Online Mindfulness-Based Cancer Recovery |
| Control group | No intervention | –Treatment as usual |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- ≥ 18 years
- Being a woman
- Being diagnosed with breast or any gynecological cancer (either ovarian, cervical, vulvar, womb or vaginal cancer), stages I to IV.
- For women with localized cancers: having completed all adjuvant treatments, such as surgery, chemotherapy and/or radiotherapy, at least 3 months previously, with the exception of hormonal, immune and targeted therapy,
- For women with metastatic cancers: having a performance status < 3, not undergoing IV chemotherapy and having a life expectancy more than 9 months as estimated by their treating oncologist.
Key exclusion criteria (13 listed)
- Inability to follow the procedures of the study due to:
- Currently engages in meditation one or more times per week
- Previous participation in an MBI program
- Serious physiological illnesses that would interfere with the interpretation of biochemical data (e.g., anemia, diabetes, cardiovascular diseases, blood cancers, inflammatory bowel diseases, autoimmune diseases, asthma being treated with steroids, immunodeficiency)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Online Mindfulness-Based Cancer Recovery (MBCR)Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools. | Behavioural | Intervention group |
Primary outcome
Participants' attendance to the program
Time frame: Within 3 weeks of completion of the intervention
Number of overall sessions attended - patients are expected to attend at least 5 of the 10 sessions planned (including the 6-h retreat)
27 secondary outcomes
Acceptability of the program (quantitative)
Time frame: Every week during the intervention and within 3 weeks of completion of the intervention
Acceptability of the program (qualitative)
Time frame: Every week during the intervention and within 3 weeks of completion of the intervention
Appropriateness of the program (quantitative)
Time frame: Within 3 weeks of completion of the intervention
Appropriateness of the program (qualitative)
Time frame: Within 3 weeks of completion of the intervention
Fidelity of the program
Time frame: Within 3 weeks of completion of the intervention
Adoption of the program (from participants' perspectives)
Time frame: Organizational: within 3 weeks of completion of the intervention ; participants: 3-month follow up from intervention completion
Adoption of the program (from professionals' perspectives)
Time frame: Organizational: within 3 weeks of completion of the intervention ; participants: 3-month follow up from intervention completion
Costs of the program
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Time to recruit, recruitment, retention rates, reasons for non-participation and acceptability of data collection
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Acceptability of the study processes
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Patients' experience related to the online MBCR program and the study design
Time frame: Within 3 weeks of completion of the intervention
State and Trait Anxiety Inventory Form Y (STAI-Y)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Major Depression Inventory (MDI)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Five Facet Mindfulness Questionnaire (FFMQ)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Sleep Condition Indicator (SCI)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Posttraumatic Growth Inventory - Revised (PTGI-R)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Self-Compassion Scale (SCS)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Fear of Cancer Recurrence Inventory (FCRI)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Functional Assessment of Chronic Illness Therapy Spiritual Well-Being (FACIT-Sp12)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Immune cells count
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Circulating pro-inflammatory markers (1)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Circulating pro-inflammatory markers (2)
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Gene expression of pro-inflammatory genes
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Telomerase activity
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Telomere length
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Methylation of inflammatory genes
Time frame: Pre-intervention, within 3 weeks of completion of the intervention, 3-month follow up from intervention completion
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Nov 2022.
- Derived from this study: PubMed 41272951Gaignard ME, Martin D, Stanic J, Hilfiker R, Bodmer A, Ljuslin M, Zaman K, Labidi-Galy I, Sarivalasis A, Carlson LE, Peters S, Dietrich PY, Eicher M, Bondolfi G, Jermann F. The Experience of Women With Breast or Gynecological Cancer After Participation in an Online Mindfulness-Based Cancer Recovery (e-MBCR) Program: Secondary Outcomes Analysis of a Pilot Mixed Methods Randomized Controlled Trial. Psychooncology. 2025 Nov;34(11):e70334. doi: 10.1002/pon.70334.
- Individual participant dataSharing planned: No
Related trials for Gynecologic Cancer
RecruitingPhase 2
Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial)
Malignant Female Reproductive System Neoplasm, Malignant Solid Neoplasm
Recruiting
INtegrating Systematic PatIent-Reported Evaluations in Multi-Disciplinary Tumor Boards: The INSPIRE Study
Breast Cancer, Corpus Uteri Cancer
Not yet recruiting
Gut Microbiome in Patients With Lung and Melanoma Cancer and Intestinal Microbiota in Gynecologic Cancers
Non Small Cell Lung Cancer, Melanoma (Skin Cancer)
Enrolling by invitation
Peer Ambassador in Gyn Onc Trials
Ovarian Cancer
RecruitingObservational study
Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study
Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Online Mindfulness-Based Cancer Recovery (MBCR) in people with Gynecologic Cancer, run by University Hospital, Geneva at 2 sites in Switzerland.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Participants' attendance to the program (time frame: Within 3 weeks of completion of the intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04564768, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Nov 2022.